References
1. Karas DJ, Bandari J, Browning DN, Jacobs BL, Davies BJ. Payments to
Pediatricians in the Sunshine Act. Clinical Pediatrics .
2017/07/01 2016;56(8):723-728. doi:10.1177/0009922816670981
2. Sampson MR, Benjamin DK, Cohen-Wolkowiez M. Evidence-based guidelines
for pediatric clinical trials: focus on StaR Child Health. Expert
review of clinical pharmacology . 2012;5(5):525-531.
doi:10.1586/ecp.12.52
3. Medicine AFABoI, Medicine A-AFACoP-ASoI, European Federation of
Internal M. Medical professionalism in the new millennium: a physician
charter. Ann Intern Med . Feb 5 2002;136(3):243-6.
doi:10.7326/0003-4819-136-3-200202050-00012
4. Tarras ES, Marshall DC, Rosenzweig K, Korenstein D, Chimonas S.
Trends in Industry Payments to Medical Oncologists in the United States
Since the Inception of the Open Payments Program, 2014 to 2019.JAMA Oncology . 2021;7(3):440-444. doi:10.1001/jamaoncol.2020.6591
5. Pokorny AMJ, Fabbri A, Bero LA, Moynihan R, Mintzes BJ. Interactions
with the pharmaceutical industry and the practice, knowledge and beliefs
of medical oncologists and clinical haematologists: a systematic review.British Journal of Cancer . 2021/10/01
2021;doi:10.1038/s41416-021-01552-1
6. Murayama A, Ozaki A, Saito H, et al. Pharmaceutical company payments
to dermatology Clinical Practice Guideline authors in Japan. PLoS
One . 2020;15(10):e0239610. doi:10.1371/journal.pone.0239610
7. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial
and Intellectual Conflicts of Interest Among Japanese Clinical Practice
Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck
Surg . Aug 17 2021;0(0):1945998211034724. doi:10.1177/01945998211034724
8. Ozaki A, Saito H, Onoue Y, et al. Pharmaceutical payments to
certified oncology specialists in Japan in 2016: a retrospective
observational cross-sectional analysis. BMJ Open . Sep 6
2019;9(9):e028805. doi:10.1136/bmjopen-2018-028805